Elixir meets primary endpoint for novel coronary device

Elixir meets primary endpoint for novel coronary device

Submitted by admin on October 26, 2023 - 10:31am
Source: 
Clinical Trials Arena
News Tags: 
Elixir
drug-eluting stents
DESyne BDS
Medtech
cliincal trials
Headline: 
Elixir meets primary endpoint for novel coronary device
snippet: 

The DESyne BDS drug-eluting stent achieved a 1.0% target lesion failure rate compared to 8.2% by the durable polymer drug-eluting stent.

Do Not Allow Advertisers to Use My Personal information